Are weight loss drugs safe? Learn some of the side effects
Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few years. Part of that controversy deals with the side effects caused by some of the more well-known medications like Ozempic and Mounjaro. According to the Obesity Medicine Association (OMA), researchers are continually analyzing the pros […]
Novo Nordisk announces CEO transition as share price slips
Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight loss drugs. The Ozempic maker’s chief executive Lars Fruergaard Jorgensen first joined the company as an economist in 1991. Jorgensen has served as Novo Nordisk’s CEO since 2017, leading the company […]
Boosting Muscle and Fat Loss with GLP-1s
This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While these powerful weight loss drugs are effective, a significant portion of the lost weight is lean body mass, raising concerns about potential long-term effects on physical function and health. Several investigational drugs, including SARMs and antimostatin agents, […]
Protein Drinks Keep Punching, As Core Brands Grow and Occasions Expand
The protein-in-everything trend has flared up at times over the past decade, but current conditions — with tailwinds from health and wellness now supercharged by the arrival of Ozempic and GLP-1 drugs — only seem to be growing more favorable.
“Ozempic Tongue” Is The Latest “Nasty” Side Effect Of Weight-Loss Meds, As More Celebs Speak Out
A growing number of users say Ozempic is rewiring their taste buds in ways they never saw coming. The blockbuster weight loss drug isn’t just shrinking waistlines. It’s changing how people experience food altogether, leading to the phenomenon that’s now being called the Ozempic tongue. It takes away “all the joy of eating away,” one said […]
Who deserves weight-loss drugs? | David A Kessler
The struggle to obtain these medications illustrates the dangerous mess the US healthcare system has become, writes the former FDA chief The American healthcare system is broken. It is too complicated and too hard for people to get the care and medications they need. More than 70% of Americans feel it has failed them. The […]
Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for type 2 diabetes (T2DM), obesity, and cardiovascular disease.1–3 Beyond these indications, they have shown promising clinical efficacy in conditions such as chronic kidney disease, metabolic dysfunction–associated steatohepatitis, obstructive sleep apnea, and Parkinson’s disease.4–6 With proven efficacy and increasing global use, there is a growing need […]
STAT+: Pharmalittle: We’re reading about Novo Nordisk CEO stepping down, hospitals making drugs, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, for the most part, is rather modest. We plan to catch up on our reading, promenade with the official mascots, hang out at […]
Semaglutide and Lower Fracture Risk Versus Sleeve Gastrectomy
According to an article in Medscape Medical News, a study presented at the AACE 2025 conference indicates that individuals treated for obesity using semaglutide (Wegovy) may experience a significantly lower risk of fractures compared to those who undergo sleeve gastrectomy. Researchers utilized electronic health record data and observed a 26% reduction in fracture risk for the semaglutide group over a three-year period. The study […]
GLP-1 Agonists Reduce Recurrent Atrial Fibrillation
Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report investigators who say weight loss does not fully explain the benefit. Medscape Medical News